

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

INSIDE INFORMATION ANNOUNCEMENT
COMMENCEMENT OF INDEPENDENT
THIRD PARTY INVESTIGATION

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

FORMATION OF SPECIAL INVESTIGATION GROUP

References are made to the incident disclosed in the inside information announcement of the Company dated 15 January 2024 (the “**Incident**”). As of the date of this announcement, the Company has established an independent third-party investigation group (the “**Special Investigation Group**”) to conduct a comprehensive investigation into the Incident.

The Special Investigation Group is led by independent non-executive directors of the Company and has entrusted a leading international forensic investigation team to conduct the investigation in collaboration with a renowned international law firm. The Special Investigation Group will use methods such as IT data recovery and retrieval, document review, key personnel interviews, internal control testing, etc., and combine the police investigation situation and progress to carefully assess the substance and impact of the Incident. It will comprehensively review the potential issues and weaknesses in the internal controls of the Company’s subsidiaries, especially the overseas subsidiaries. The Special Investigation Group will ascertain the factual truth, restore the essence of the Incident, clarify the relevant responsibilities, and prepare an independent verification report to report to the Company’s board of directors (the “**Board**”) no later than the publication of the Company’s 2023 annual report. The report will also be published for the information of potential investors of the Company simultaneously.

In addition to establishing the Special Investigation Group, the Company is working with the local police and making every effort to recover the funds, and is conducting comprehensive work to strengthen internal controls. This includes revising and improving various management systems and operational procedures, strengthening and perfecting the internal control system, hiring internal and external risk control experts, enhancing training on internal controls, raising risk awareness, and strengthening the awareness of all employees, both domestically and internationally, to prevent fraud. The Company is also continuously enhancing network and communication infrastructure security management to ensure the security of network information, among other measures.

The Company will strictly comply with the provisions and requirements of the relevant laws and regulations, seriously fulfill its information disclosure obligations, and strive to manage its operations and corporate governance.

Shareholders and potential investors of the Company are reminded that the information provided in this announcement is based on the currently available information to the Board. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
January 30, 2024

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.